Skip to content
Advertisement

As investors pile into psychedelics, idealism gives way to pharma economics

FILE - Rick Doblin, the founder and director of the Multidisciplinary Association for Psychedelic Studies, or MAPS, stands for a portrait in Vista, Calif., on Aug. 15, 2018. On principle, the group’s pharmaceutical arm, has never patented its work. But as investment opportunities have multiplied, charitable donations have dried up. The group was recently forced to take on private investors to continue funding the drug company, which recently changed its name to Lykos Therapeutics. “We’re a victim of our own success,” said Doblin. “It’s heartbreaking because I had hoped to go the whole way with philanthropy, but I was unable to raise all the mega millions to do that.” (AP Photo/Gregory Bull, File)
FILE - Rick Doblin, the founder and director of the Multidisciplinary Association for Psychedelic Studies, or MAPS, stands for a portrait in Vista, Calif., on Aug. 15, 2018. On principle, the group’s pharmaceutical arm, has never patented its work. But as investment opportunities have multiplied, charitable donations have dried up. The group was recently forced to take on private investors to continue funding the drug company, which recently changed its name to Lykos Therapeutics. “We’re a victim of our own success,” said Doblin. “It’s heartbreaking because I had hoped to go the whole way with philanthropy, but I was unable to raise all the mega millions to do that.” (AP Photo/Gregory Bull, File)

More Photo Galleries

Jones.jpg

Top 10 handguns in the U.S.

The most prolific makes of handguns manufactured in the U.S., based on production statistics provided to ATF.